AR039408A1 - Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento - Google Patents

Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento

Info

Publication number
AR039408A1
AR039408A1 ARP030101279A ARP030101279A AR039408A1 AR 039408 A1 AR039408 A1 AR 039408A1 AR P030101279 A ARP030101279 A AR P030101279A AR P030101279 A ARP030101279 A AR P030101279A AR 039408 A1 AR039408 A1 AR 039408A1
Authority
AR
Argentina
Prior art keywords
dry powder
pharmaceutical composition
manufacture
inhalation therapy
medicinal product
Prior art date
Application number
ARP030101279A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR039408A1 publication Critical patent/AR039408A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones farmacéuticas en polvo seco con estabilidad mejorada que comprenden un fármaco broncodilatador en combinación con un fármaco anti-inflamatorio esteroideo, inhaladores de polvo seco que comprenden las mismas y su uso en el tratamiento de trastornos respiratorios por inhalación. Reivindicación 1: Una composición farmacéutica en polvo seco para terapia por inhalación, que comprende salmeterol o una sal farmacéuticamente aceptable del mismo y propionato de fluticasona, un excipiente y un carbohidrato derivatizado en forma particulada.
ARP030101279A 2002-04-13 2003-04-11 Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento AR039408A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0208609.8A GB0208609D0 (en) 2002-04-13 2002-04-13 Compositions

Publications (1)

Publication Number Publication Date
AR039408A1 true AR039408A1 (es) 2005-02-16

Family

ID=9934856

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101279A AR039408A1 (es) 2002-04-13 2003-04-11 Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento

Country Status (19)

Country Link
US (2) US20050232998A1 (es)
EP (1) EP1509199A1 (es)
JP (1) JP2005529874A (es)
KR (1) KR20040097348A (es)
CN (1) CN100362986C (es)
AR (1) AR039408A1 (es)
AU (1) AU2003224278A1 (es)
BR (1) BR0309115A (es)
CA (1) CA2482249A1 (es)
GB (1) GB0208609D0 (es)
IL (1) IL164421A0 (es)
IS (1) IS7501A (es)
MX (1) MXPA04010082A (es)
NO (1) NO20044496L (es)
PL (1) PL373293A1 (es)
RU (1) RU2004130438A (es)
TW (1) TW200407174A (es)
WO (1) WO2003088944A1 (es)
ZA (1) ZA200408247B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507881A (ja) 2001-09-17 2005-03-24 グラクソ　グループ　リミテッド 乾燥粉末医薬製剤
EP1643974A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Inhalable pharmaceutical formulations comprising a sugar ester
NZ556709A (en) 2005-02-10 2009-09-25 Glaxo Group Ltd Process for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
GB0605723D0 (en) 2006-03-23 2006-05-03 3M Innovative Properties Co Powder filling processes
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
CA2697495C (en) * 2007-09-05 2013-02-05 Pfizer Limited Xinafoate salt of n4-[(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine
TR201007251A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Kalsiyum kanal blokörü formülasyonu.
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
CN104703584B (zh) * 2012-02-28 2019-05-31 艾塞尤提卡控股公司 可吸入药物组合物
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
PL3517541T3 (pl) 2012-05-08 2020-12-28 Nicox Ophthalmics, Inc. Postać polimorficzna propionianu flutykazonu
KR102069925B1 (ko) 2012-07-19 2020-01-23 아다미스 파마슈티칼스 코포레이션 분말 공급 장치
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
AU2014261538A1 (en) * 2013-04-29 2015-12-10 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them
CN104644618A (zh) * 2013-11-19 2015-05-27 上海医药工业研究院 一种干粉吸入剂及其制备方法
AU2015296142A1 (en) * 2014-07-31 2017-02-23 Otitopic Inc. Dry powder formulations for inhalation
KR20160038767A (ko) * 2014-09-30 2016-04-07 한미약품 주식회사 복합 활성성분의 안정성이 개선된 흡입 제형용 건조분말
KR20160117069A (ko) * 2015-03-31 2016-10-10 한미약품 주식회사 복합 활성성분의 안정성이 개선된 흡입용 캡슐제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) * 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
AU591152B2 (en) * 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
PT994887E (pt) * 1997-07-03 2003-04-30 Elan Drug Delivery Ltd Glicosidos modificados composicoes que compreendem os mesmos e metodos para a sua utilizacao
US6352722B1 (en) * 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
AU3664102A (en) * 2000-12-01 2002-06-11 Battelle Memorial Institute Method for stabilizing biomolecules in liquid formulations
NZ528640A (en) * 2001-03-30 2004-06-25 Jagotec Ag Medical aerosol formulations
JP2005527618A (ja) * 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト

Also Published As

Publication number Publication date
RU2004130438A (ru) 2005-06-10
TW200407174A (en) 2004-05-16
IS7501A (is) 2004-10-11
MXPA04010082A (es) 2004-12-13
US20080060645A1 (en) 2008-03-13
IL164421A0 (en) 2005-12-18
AU2003224278A1 (en) 2003-11-03
NO20044496L (no) 2004-11-15
EP1509199A1 (en) 2005-03-02
CN100362986C (zh) 2008-01-23
US20050232998A1 (en) 2005-10-20
CA2482249A1 (en) 2003-10-30
PL373293A1 (en) 2005-08-22
BR0309115A (pt) 2005-02-01
GB0208609D0 (en) 2002-05-22
WO2003088944A1 (en) 2003-10-30
KR20040097348A (ko) 2004-11-17
JP2005529874A (ja) 2005-10-06
CN1658837A (zh) 2005-08-24
ZA200408247B (en) 2006-03-29

Similar Documents

Publication Publication Date Title
AR039408A1 (es) Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento
CL2004001170A1 (es) Combinacion farmaceutica inhalable que contiene (a) formoterol, o una sal, o un solvato de el o de la sal y (b) furoato de mometasona; estuche farmaceutico que la comprende; y su uso en la terapia de una enfermedad inflamatoria u obstructiva de las v
BR0008276A (pt) Combinações de formoterol e propionato de fluticasona para asma
ES2178943B1 (es) Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica.
DE60114571D1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
JP2022180461A5 (es)
AR015820A1 (es) Particulas de budesonida, composicion farmaceutica, uso de dichas particulas para la fabricacion de medicamentos, metodo para el tratamiento de untrastorno respiratorio y proceso para la preparacion de las particulas
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
JP2007520506A5 (es)
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
ID29181A (id) Kombinasi formoterol dan garam tiotropium
UY26959A1 (es) Nuevos polvos para inhalación que contienen tiotropio
ES2062392T3 (es) Medicamentos que comprenden salmeterol y fluticasona.
BRPI0518622A2 (pt) usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento
NO179893C (no) Anvendelse av et ikke-steroidisk anti-inflammatorisk medikament for fremstilling av et legemiddel
ECSP034571A (es) Nuevas composiciones de medicamentos a base de sales de tiotropio y sales del salmeterol
BRPI0408047A (pt) medicamento contendo um agonista beta2 de longa duração altamente potente em combinação com outros princìpios ativos
AR058194A1 (es) Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide
SE0402345L (sv) Uppmätt läkemedelsdos
AR008886A1 (es) Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea
PE20020793A1 (es) Agente preventivo y/o terapeutico de enfermedades inflamatorias del tracto respiratorio
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
BR0309114A (pt) Uso de carboidratos derivados particulados em composições farmacêuticas em pó seco, composição farmacêutica em pó seco para terapia de inalação, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, e, embalagem de medicamento
JP2005508963A5 (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal